Viewing Study NCT03263260


Ignite Creation Date: 2025-12-25 @ 2:09 AM
Ignite Modification Date: 2026-01-07 @ 9:41 PM
Study NCT ID: NCT03263260
Status: COMPLETED
Last Update Posted: 2024-09-04
First Post: 2017-08-24
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent
Sponsor: Scitech Produtos Medicos Ltda
Organization:

Study Overview

Official Title: Prospective, Multicentric, Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent for Treatment of Patients With Native Coronary Artery Lesions (Inspiron Real Life II)
Status: COMPLETED
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: Inspiron RL II
Brief Summary: Post-marketing, prospective, multicentric, non-randomized registry to evaluate the safety and efficacy of Inspiron Sirolimus Eluting Coronary Stent at the treatment of "real-world" patients.
Detailed Description: Up to 5.0000 patients with native coronary arteries lesions with diameter between 2.5 and 4.0 mm and 34 mm of length treated solely with the Inspiron Sirolimus Eluting Coronary Stent.

Stent implantation should be performed according to the Instructions for Use and according to the local practice. It is recommended that ECG and cardiac enzymes are collected before and after procedure. Dual anti-platelet therapy is recommended for at least 6 months after procedure.

Patients will be followed at 30 days, 1 and 2 years after procedure.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: